Abstract
The use of biologics in the treatment of severe eosinophilic asthma (SEA) has the potential for patients achieving clinical remission. Post hoc analyses demonstrated this in controlled settings, but data are limited in the real world. We assessed clinical remission in patients treated with benralizumab in a real-world study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
